Milsaperidone (VHX-896) vs Risperidone (Rykindo)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Milsaperidone (VHX-896)
Marketed by Vanda Pharmaceuticals
NCT06494397 · Phase 1 · completed
Every participant in this trial received both VHX-896 and iloperidone, just in a different order, so there is no separate group that shows what happens without VHX-896, and nobody was blinded to which drug was being given at each stage. The trial measured drug levels in the blood to compare the two products, not any change in psychiatric symptoms, and results have not been posted yet.
No aligned efficacy figure on record for this race.
Risperidone (Rykindo)
Marketed by Luye Pharma Group
NCT02055287 · Phase 1 · completed
A non-randomized, open-label, four-dose pharmacokinetic study of Rykindo in 36 participants. With no randomization, no blinding, no comparator arm, and no results posted to the registry, this is weak evidence.
No aligned efficacy figure on record for this race.
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Milsaperidone (VHX-896) | Risperidone (Rykindo) |
|---|---|---|
| PANSS total, change | —Not reported | —Not posted · NCT00216580 |
| CGI-S, change | —Not reported | —Not posted · NCT00216580 |
| PANSS response | —Not reported | —Not posted · NCT00216580 |
| PSP, change | —Not reported | —Not posted · NCT00216580 |
| Relapse (% of patients) | —Not reported | —Not posted · NCT00216580 |
PANSS total, change
- Milsaperidone (VHX-896)
- —Not reported
- Risperidone (Rykindo)
- —Not posted · NCT00216580
CGI-S, change
- Milsaperidone (VHX-896)
- —Not reported
- Risperidone (Rykindo)
- —Not posted · NCT00216580
PANSS response
- Milsaperidone (VHX-896)
- —Not reported
- Risperidone (Rykindo)
- —Not posted · NCT00216580
PSP, change
- Milsaperidone (VHX-896)
- —Not reported
- Risperidone (Rykindo)
- —Not posted · NCT00216580
Relapse (% of patients)
- Milsaperidone (VHX-896)
- —Not reported
- Risperidone (Rykindo)
- —Not posted · NCT00216580
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Milsaperidone (VHX-896): no structured comparison results are available for Schizophrenia.
Risperidone (Rykindo): no structured comparison results are available for Schizophrenia.
Bipolar Disorder
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Bipolar Disorder pipeline
Milsaperidone (VHX-896)
Marketed by Vanda Pharmaceuticals
NCT06494397 · Phase 1 · completed
Every participant in this trial received both VHX-896 and iloperidone, just in a different order, so there is no separate group that shows what happens without VHX-896, and nobody was blinded to which drug was being given at each stage. The trial measured drug levels in the blood to compare the two products, not any change in psychiatric symptoms, and results have not been posted yet.
No aligned efficacy figure on record for this race.
Risperidone (Rykindo)
Marketed by Luye Pharma Group
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Bipolar Disorder
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Milsaperidone (VHX-896): no structured comparison results are available for Bipolar Disorder.
Risperidone (Rykindo): no structured comparison results are available for Bipolar Disorder.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Milsaperidone (VHX-896)'s landscape · Risperidone (Rykindo)'s landscape